BACKGROUND: Prohibitin (PHB), a protein located on the inner mitochondrial membrane and nuclei, is an intracellular effector of transforming growth factor-beta (TGF-beta) signaling in prostate cancer cells. This study investigated the involvement of PHB in the apoptosis and survival outcomes of human prostate cancer cell to TGF-beta. shRNA PHB loss of function in prostate cancer cells led to enhanced apoptotic response to TGF-beta via Smad-dependent mechanism. METHOD: TGF-beta activation of Raf-Erk intracellular signaling, led to PHB phosphorylation, decreased inner mitochondrial permeability, and increased cell survival. Calcein-based immunofluorescence studies revealed the functional involvement of PHB in maintaining inner mitochondrial membrane permeability as an integral component of TGF-beta induced apoptosis in prostate cancer cells. RESULTS: These finding indicates that induction of TGF-beta apoptosis is mediated by Smad-dependent and Smad-independent signaling (MAPK) converging at PHB as a downstream effector regulating inner mitochondrial permeability. Putative PHB associated proteins were identified by subjecting TGF-beta treated cells to immunoprecipitation with anti-PHB, and mass spectrometry. A screen for the kinase specific phosphorylation sites of PHB revealed three protein kinase (PKC) binding sites. CONCLUSION: Our results demonstrate that TGF-beta led to upregulation of the PKC inhibitor 14-3-3 protein and promoted its association with PHB, while PHB association with PKC-delta, was inhibited by the MEK1 inhibitor, documenting a critical interdependence between the MEK-ERK signaling and prohibitin phosphorylation. These findings suggest a dual role for PHB as a downstream determinant of the cellular response to TGF-beta via Smad-dependent pathway (apoptosis) and MAPK intracellular signaling (survival). (c) 2009 Wiley-Liss, Inc.
BACKGROUND:Prohibitin (PHB), a protein located on the inner mitochondrial membrane and nuclei, is an intracellular effector of transforming growth factor-beta (TGF-beta) signaling in prostate cancer cells. This study investigated the involvement of PHB in the apoptosis and survival outcomes of humanprostate cancer cell to TGF-beta. shRNA PHB loss of function in prostate cancer cells led to enhanced apoptotic response to TGF-beta via Smad-dependent mechanism. METHOD:TGF-beta activation of Raf-Erk intracellular signaling, led to PHB phosphorylation, decreased inner mitochondrial permeability, and increased cell survival. Calcein-based immunofluorescence studies revealed the functional involvement of PHB in maintaining inner mitochondrial membrane permeability as an integral component of TGF-beta induced apoptosis in prostate cancer cells. RESULTS: These finding indicates that induction of TGF-beta apoptosis is mediated by Smad-dependent and Smad-independent signaling (MAPK) converging at PHB as a downstream effector regulating inner mitochondrial permeability. Putative PHB associated proteins were identified by subjecting TGF-beta treated cells to immunoprecipitation with anti-PHB, and mass spectrometry. A screen for the kinase specific phosphorylation sites of PHB revealed three protein kinase (PKC) binding sites. CONCLUSION: Our results demonstrate that TGF-beta led to upregulation of the PKC inhibitor 14-3-3 protein and promoted its association with PHB, while PHB association with PKC-delta, was inhibited by the MEK1 inhibitor, documenting a critical interdependence between the MEK-ERK signaling and prohibitin phosphorylation. These findings suggest a dual role for PHB as a downstream determinant of the cellular response to TGF-beta via Smad-dependent pathway (apoptosis) and MAPK intracellular signaling (survival). (c) 2009 Wiley-Liss, Inc.
Authors: Carsten Merkwirth; Sascha Dargazanli; Takashi Tatsuta; Stefan Geimer; Beatrix Löwer; F Thomas Wunderlich; Jürgen-Christoph von Kleist-Retzow; Ari Waisman; Benedikt Westermann; Thomas Langer Journal: Genes Dev Date: 2008-02-15 Impact factor: 11.361
Authors: Michael Schleicher; Benjamin R Shepherd; Yajaira Suarez; Carlos Fernandez-Hernando; Jun Yu; Yong Pan; Lisette M Acevedo; Gerald S Shadel; William C Sessa Journal: J Cell Biol Date: 2008-01-14 Impact factor: 10.539
Authors: Daniel M Rotroff; Sonja S Pijut; Skylar W Marvel; John R Jack; Tammy M Havener; Aurora Pujol; Agatha Schluter; Gregory A Graf; Henry N Ginsberg; Hetal S Shah; He Gao; Mario-Luca Morieri; Alessandro Doria; Josyf C Mychaleckyi; Howard L McLeod; John B Buse; Michael J Wagner; Alison A Motsinger-Reif Journal: Clin Pharmacol Ther Date: 2017-11-03 Impact factor: 6.875
Authors: Srinivas R Sripathi; Weilue He; O'Donnell Sylvester; Musa Neksumi; Ji-Yeon Um; Thagriki Dluya; Paul S Bernstein; Wan Jin Jahng Journal: Protein J Date: 2016-06 Impact factor: 2.371